Abstract
The COVID-19 pandemic has caused over half a million deaths in Brazil, and public healthcare nearly collapsed. Vaccination differs between states and demographics. Dose shortages delayed access.
In this cross-sectional study, data were retrieved from the Brazilian Ministry of Health databases published since 17 January 2021, respectively. We developed a campaign optimality index to characterise inequality in vaccination access caused by age due to premature vaccination towards younger populations before older and vulnerable populations were fully vaccinated. We assessed geographical inequalities in full vaccination coverage and dose by age, sex, race, and socioeconomic status. Generalised linear regression was used to investigate the risk of death and hospitalisation by age group, socioeconomic status, and vaccination coverage.
Vaccination coverage is higher in the wealthier South and Southeast. Men, people of colour, and low-income groups were more likely to be only partially vaccinated due to missing or delaying a second dose. Vaccination started prematurely for age groups under 50 years and may have hindered uptake of older age groups. Vaccination coverage was associated with a lower risk of death, especially in older age groups (OR: 10.5–34.8, 95% CI: (10.2, 35.9)). Risk of hospitalisation was greater in areas with higher vaccination rates due to higher access to care and reporting.
Vaccination inequality persists between states, age and demographic groups despite increasing uptake. The association between hospitalisation rates and vaccination is attributed to preferential delivery to areas of greater transmission and access to healthcare.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
SLL was supported by the Oxford Martin Programme on Pandemic Genomics and the Canadian Social Sciences and Humanities Research Council (SSHRC) Doctoral Fellowship. CAPJ is supported by FAPESP (2019/21858-0 and 2022/15985-1). AEZ was supported by the Oxford Martin School Programme on Pandemic Genomics. CAPJ and VHN were supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brasil (CAPES) Finance Code 001. VHN is supported by the Brazilian National Council for Scientific and Technological Development (CNPq: 304714/2018- 6). ECS is supported by a Medical Research Council Sao Paulo Research Foundation (FAPESP) CADDE partnership award (MR/S0195/1 and FAPESP 18/14389-0) (http://caddecentre.org/).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project was approved by the Brazilian National Research Ethics Committee (CONEP CAAE-30178220.3.1001.0068). This study used only openly available data that were originally located at https://opendatasus.saude.gov.br/dataset/srag-2020 https://opendatasus.saude.gov.br/dataset/srag-2021-a-2023 https://opendatasus.saude.gov.br/dataset/covid-19-vacinacao
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
